Order Article Reprints

Kupryś-Lipińska I, Tworek D, Vanderbist F, Bocheńska-Marciniak M, Kuna P. Efficacy and Safety of a 12-Week Therapy with a New Formulation of Fluticasone Propionate at Doses of 125 and 250 μg Administered through a New Generation Cyclohaler Twice Daily, in Comparison to Fluticasone Propionate 500 μg Dry Powder Inhaler Twice Dail in Patients with Moderate Asthma. Advances in Respiratory Medicine. 2013; 81(6):527-536. https://doi.org/10.5603/ARM.35994

Kupryś-Lipińska, Izabela, Damian Tworek, Francis Vanderbist, Małgorzata Bocheńska-Marciniak, and Piotr Kuna. 2013. "Efficacy and Safety of a 12-Week Therapy with a New Formulation of Fluticasone Propionate at Doses of 125 and 250 μg Administered through a New Generation Cyclohaler Twice Daily, in Comparison to Fluticasone Propionate 500 μg Dry Powder Inhaler Twice Dail in Patients with Moderate Asthma" Advances in Respiratory Medicine 81, no. 6: 527-536. https://doi.org/10.5603/ARM.35994

Kupryś-Lipińska, I., Tworek, D., Vanderbist, F., Bocheńska-Marciniak, M., & Kuna, P. (2013). Efficacy and Safety of a 12-Week Therapy with a New Formulation of Fluticasone Propionate at Doses of 125 and 250 μg Administered through a New Generation Cyclohaler Twice Daily, in Comparison to Fluticasone Propionate 500 μg Dry Powder Inhaler Twice Dail in Patients with Moderate Asthma. Advances in Respiratory Medicine, 81(6), 527-536. https://doi.org/10.5603/ARM.35994